1
|
Hargarter L, Bergmans P, Cherubin P, Schreiner A. Early schizophrenia patients treated with once-monthly paliperidone palmitate over a 12-month period - a retrospective observational study. Eur Psychiatry 2020. [DOI: 10.1016/j.eurpsy.2016.01.637] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
IntroductionLittle is known about patient characteristics and rehospitalization in newly diagnosed patients with schizophrenia treated with long-acting antipsychotics.ObjectivesTo retrospectively explore hospitalizations, drug utilization and clinical outcomes from medical records of young, newly diagnosed schizophrenia patients during the first 12 months of treatment with once-monthly paliperidone palmitate (PP).MethodsInternational, multicenter, retrospective, observational study. Outcomes presented are patient characteristics, reason for PP initiation and hospitalization data.ResultsEighty-four patients were analyzed: mean age (years) at first psychotic episode was 23.8 (SD2.6), 23.9 (SD2.6) at first antipsychotic treatment and 24.1 (SD2.7, range 19-29) at PP initiation. Time between first antipsychotic treatment and PP initiation was 4.8 (SD: 3.4, range: 0-12) months. At PP initiation, 42.9% of patients were in hospital, primarily for the management of the first episode/relapse (97.2%). Reason for PP initiation was: LAT favored over oral treatment for relapse prevention (56%), partial/non adherence with previous oral medication (20.0%), convenience (15.5%) or limited access to health care systems (2.4%). Mean time (days) between admission and initiation of PP, and between initiation of PP and discharge from hospital was 28.8 (SD23.0) and 23.2 (SD24.5), respectively. 96.4% of patients were not hospitalized during the 12-month PP treatment period. 3/84 patients (3.6%) had a single hospitalization of 15.7 (SD: 8.1) days for management of episode/relapse.ConclusionsIn this young, newly diagnosed schizophrenia population, the number of hospitalizations following PP initiation was low. Main reason to initiate PP was clinicians favoring LAT over oral antipsychotic treatment for relapse prevention or due to partial/non adherence with previous oral treatment.Disclosure of interestThe authors have not supplied their declaration of competing interest.
Collapse
|
2
|
Mathews M, Gopal S, Nuamah I, Hargarter L, Savitz AJ, Kim E, Tan W, Soares B, Correll CU. Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia. Neuropsychiatr Dis Treat 2019; 15:1365-1379. [PMID: 31190840 PMCID: PMC6535080 DOI: 10.2147/ndt.s197225] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/06/2018] [Accepted: 04/02/2019] [Indexed: 12/11/2022] Open
Abstract
Antipsychotics are the mainstay in schizophrenia management, and long-acting injectable (LAI) antipsychotics contribute to the successful maintenance of treatment by improving non-adherence and preventing relapses. Paliperidone palmitate 3-monthly (PP3M) formulation is the only available LAI antipsychotic that offers an extended 3-month window of stable plasma drug concentration, enabling only four injections per year. This paper summarizes clinically relevant endpoints from available evidence for PP3M to bridge translational research gaps and provide measurable outcomes that can be interpreted in clinical practice. Low number-needed-to-treat (NNT) for relapse prevention (NNT [95% CI] 6-month estimate: 4.8 [3.2; 10.0]; 12-month estimate: 3.4 [2.2; 7.0]), and high number-needed-to-harm (NNH [95% CI] akathisia, 27.1 [12.3; -667.1]; tremor, 80.0 [22.5; 67.3]; dyskinesia, -132.6 [44.5; -23.2]; parkinsonism, 160.0 [28.9; -49.8]) quantify the relative benefits and low propensity for adverse events with PP3M. Symptom remission and reductions in positive and negative symptoms indicate treatment stability. Additionally, meaningful functional remission, reduced dosing frequency, and freedom from daily negotiations favorably impact patient preference and attenuate burdensome aspects of caregiving, representing important healthcare determinants that enhance prospects of treatment continuity in schizophrenia. This information can potentially improve clinicians' judgment of treatment choices, clinical response, and patient selection in routine care. Taken together, PP3M is a valuable antipsychotic treatment option, meriting consideration for a broader role in the long-term management of schizophrenia; its utility should not be limited to patients with poor adherence or when oral antipsychotics have failed.
Collapse
Affiliation(s)
- Maju Mathews
- Department of Neuroscience, Janssen Research & Development, LLC, Raritan, NJ, USA
| | - Srihari Gopal
- Department of Neuroscience, Janssen Research & Development, LLC, Raritan, NJ, USA
| | - Isaac Nuamah
- Department of Neuroscience, Janssen Research & Development, LLC, Raritan, NJ, USA
| | - Ludger Hargarter
- Department of Neuroscience, Janssen-Cilag EMEA, Neuss, Deutschland
| | - Adam J Savitz
- Department of Neuroscience, Janssen Research & Development, LLC, Raritan, NJ, USA
| | - Edward Kim
- Janssen Scientific Affairs, LLC, Hopewell, NJ, USA
| | - Wilson Tan
- Regional Medical Affairs, Janssen Pharmaceutical Companies of Johnson and Johnson, Singapore
| | - Bernardo Soares
- Neuroscience Medical Affairs, Janssen-Cilag, High Wycombe, Buckinghamshire, UK
| | - Christoph U Correll
- The Zucker Hillside Hospital, Psychiatry Research, Glen Oaks, NY, USA
- Department of Psychiatry and Molecular Medicine, Hofstra Northwell School of Medicine, East Garden City, NY, USA
- Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany
| |
Collapse
|
3
|
Hargarter L, Lahaye M, Cherubin P, Lambert M, Swarz M, Joldygulov G, Vischia F, Chomskaya V, Bozikas VP, Tsapakis EM, Schreiner A. Treatment response and tolerability with once-monthly paliperidone palmitate initiated shortly after hospital admission in patients with schizophrenia. World J Biol Psychiatry 2019; 19:S147-S157. [PMID: 28594264 DOI: 10.1080/15622975.2017.1315176] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
OBJECTIVES Partial or non-adherence in patients with schizophrenia is common and increases the risk of relapse. This study explored safety, tolerability and treatment outcomes in patients hospitalised for an exacerbation of schizophrenia initiated on maintenance treatment of once-monthly paliperidone palmitate (PP1M). METHODS A 6-week, observational cohort study of patients initiated on PP1M within 3 weeks after hospital admission. RESULTS Overall, 367 patients were documented, 85.8% with paranoid schizophrenia subtype. Mean time from hospital admission to PP1M initiation was 9.4 ± 7.7 days. Treatment-emergent adverse events were reported by 22.9% of patients. From baseline to endpoint, significant improvements were observed in psychotic symptoms (Brief Psychiatric Rating Scale total score mean change -19.3 ± 12.6, P < .0001) and functioning (Personal and Social Performance scale total score mean change 14.3 ± 12.4, P < .0001). Overall, 6.0% of patients were very or extremely satisfied with their prior antipsychotic medication at baseline compared with 47.2% very or extremely satisfied with PP1M treatment at endpoint. CONCLUSIONS Initiating PP1M in patients with exacerbated schizophrenia shortly after hospital admission was well tolerated and resulted in statistically significant and clinically relevant improvements in symptoms and patient functioning, suggesting that patients may benefit from early initiation of PP1M during their hospital stay.
Collapse
Affiliation(s)
- Ludger Hargarter
- a Medical & Scientific Affairs , Janssen Cilag EMEA , Neuss , Germany
| | - Marjolein Lahaye
- b Biostatistics & Programming , Janssen Cilag Benelux , Tilburg , The Netherlands
| | - Pierre Cherubin
- c Medical Affairs , Janssen Cilag EMEA , Issy-les-Moulineaux , France
| | - Martin Lambert
- d University Medical Center, Eppendorf , Hamburg , Germany
| | | | - Gali Joldygulov
- f Republican Scientific Center of Psychiatry , Almaty , Kazakhstan
| | - Flavio Vischia
- g Dipartimento di Salute Mentale , Ospedale Amedeo di Savoia , Torino , Italy
| | - Veronica Chomskaya
- h State Institution of Healthcare City Psychoneurological Dispensary #3 , St Petersburg , Russia
| | - Vasilis P Bozikas
- i 1st Psychiatric Clinic of the Aristotle University of Thessaloniki, General Hospital "Papageorgiou" , Thessaloniki , Greece
| | | | - Andreas Schreiner
- a Medical & Scientific Affairs , Janssen Cilag EMEA , Neuss , Germany
| |
Collapse
|
4
|
Savitz AJ, Xu H, Gopal S, Nuamah I, Ravenstijn P, Hough D, Hargarter L. Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population. Neuropsychiatr Dis Treat 2019; 15:587-602. [PMID: 30863080 PMCID: PMC6391122 DOI: 10.2147/ndt.s189668] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
PURPOSE This randomized, double-blind (DB), non-inferiority phase 3 study was conducted to assess the efficacy and safety of paliperidone palmitate 3-month (PP3M) vs 1-month formulation (PP1M) in European and non-European patients with schizophrenia. PATIENTS AND METHODS In this randomized, DB, parallel-group study, adult patients (18-70 years) with schizophrenia (per DSM-IV-TR) having Positive and Negative Syndrome Scale (PANSS) total score between 70 and 120; previously stabilized on PP1M were enrolled. The study had 4 phases: screening (3 weeks), open-label (OL) stabilization (17 weeks), DB (48 weeks) and follow-up (4-12 weeks) phase. Patients were treated with fixed-dose PP3M (175-525 mg eq deltoid/gluteal) or PP1M (50-150 mg eq deltoid/gluteal) for 48 weeks in DB phase. RESULTS In total, 487 European (PP3M, n=242; PP1M, n=245) and 508 non-European patients (PP3M, n=241; PP1M, n=267) entered DB phase (modified intent-to-treat (mITT) [DB] analysis set). Among the 508 non-European patients in mITT set, 67.7% were from Asia (n=344) and 32.3% were from rest of world (ROW, n=164). During the DB phase, similar percentage of Europeans (PP3M: 7%; PP1M: 8%) and non-Europeans (PP3M: 9%; PP1M: 10%) experienced relapse (Kaplan-Meier estimate PP3M-PP1M [95% CI] of percentage of relapse-free patients at the end of DB phase [primary endpoint]: European: 1.0% [-4.3%; 6.2%]; non-European: 1.4% [-4.4%; 7.1%]; Asian: 1.6% [-5.7%; 9.0%]; and ROW: 1.4% [-7.0%, 9.8%], per-protocol analysis set). Incidence of treatment-emergent adverse events (TEAEs) was lower in Europeans (PP3M: 56%, PP1M: 59%) than non-Europeans (PP3M: 80%, PP1M: 73%). The most commonly reported TEAE was weight gain. CONCLUSION PP3M showed similar efficacy to PP1M in Europeans and non-Europeans, consistent with non-inferiority of PP3M to PP1M observed in overall population. Rates of AEs were higher in non-Europeans. However, weight gain was greater in non-Europeans, especially the Asian population.
Collapse
Affiliation(s)
- Adam J Savitz
- Janssen Research & Development, LLC, Raritan, NJ, USA,
| | - Haiyan Xu
- Janssen Research & Development, LLC, Raritan, NJ, USA,
| | - Srihari Gopal
- Janssen Research & Development, LLC, Raritan, NJ, USA,
| | - Isaac Nuamah
- Janssen Research & Development, LLC, Raritan, NJ, USA,
| | - Paulien Ravenstijn
- Janssen Research & Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium
| | - David Hough
- Janssen Research & Development, LLC, Raritan, NJ, USA,
| | - Ludger Hargarter
- Medical & Scientific Affairs, Janssen Cilag EMEA, Neuss, Germany
| |
Collapse
|
5
|
Hargarter L. Pharmazeutische Forschung in der Schizophrenie – Im Spannungsfeld zwischen Wissenschaft, Klinik, Politik und unternehmerischer Verantwortung. Drug Res (Stuttg) 2017; 67:S11-S12. [PMID: 29069676 DOI: 10.1055/s-0043-118156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
6
|
Hargarter L, Gopal S, Xu H, McQuarrie K, Savitz A, Nuamah I, Woodruff K, Mathews M. Effect of Two Long-acting Treatments, The Paliperidone Palmitate 1-month and 3-month Formulations on Caregiver Burden in European patients with Schizophrenia. Eur Psychiatry 2017. [DOI: 10.1016/j.eurpsy.2017.01.2141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Abstract
IntroductionSchizophrenia puts a significant burden on caregivers.ObjectivesTo explore the effects of two long-acting treatments (LAT), paliperidone palmitate 1-month and 3-month formulations on caregiver burden (CGB) in European patients with schizophrenia using the Involvement Evaluation Questionnaire (IEQ)AimsTo conduct a subgroup analysis of two randomized, double-blind studies (NCT01515423 and NCT01529515).MethodsCaregivers (≥ 1 h of contact/week with the patients) were offered to complete the IEQ (31 items, each scoring: 0–4; total score: sum of 27 items [0–108]).ResultsAmong 756 European caregivers (53% parents, 18% spouse/partner or girl/boyfriend, 10% sister/brother), 60% reported a CGB of ≥ 32 hours/week at open-label baseline (BL-OL). CGB reduced significantly for patients with both BL-OL and at least one double-blind IEQ sum-score (n = 433): mean improvement [SD] (9.9 [12.66], P < 0.001) from BL-OL (mean [SD] 26.0 [13.30]) to study end (16.0 [10.47]); (reduction in burden associated with worrying [2.9 points] and urging [4.3 points]). CGB significantly improved in patients on prior oral antipsychotics post-switching to LAT with less leisure days impacted and less hours spent in caregiving (P < 0.001). There was significant relationship between improvements and relapse status, patient age (P < 0.001), age at diagnosis (P < 0.002), and number of prior psychiatric hospitalizations in the last 24 months (P < 0.05). Prior use of long-acting antipsychotics other than paliperidone palmitate 1-month or 3-month formulations at BL-OL and duration of prior psychiatric hospitalizations in the last 24 months did not show significant effect on improvements.ConclusionSwitching from an oral antipsychotic to an LAT can provide a meaningful and significant improvement in caregiver burden.Disclosure of interestAll authors are employees of Janssen Research & Development, LLC and hold stocks in the company.
Collapse
|
7
|
Cherubin P, Maria C, Hargarter L, Wooller A. Awareness of and satisfaction with available treatment options in schizophrenia: Results from a survey of patients and caregivers in Europe. Eur Psychiatry 2017. [DOI: 10.1016/j.eurpsy.2017.02.419] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Abstract
IntroductionUnderstanding beliefs and concerns of patients with schizophrenia and their caregivers, regarding treatment options, is key to improving their care. Perceived fears can impact adherence to therapy and represent a barrier to prescribers when discussing treatment decisions.ObjectivesExplore patient and caregiver awareness of and satisfaction with available treatment options.MethodsIndependent market research agency commissioned by Janssen, performed an online European survey in 2016 to capture demographics, awareness of available therapies, current treatment satisfaction and adherence from patients with schizophrenia and caregivers.ResultsResults from 166 patients with schizophrenia and 468 caregivers from 12 European countries (France, Germany, UK, Italy, Spain, Denmark, Russia, Sweden, Austria, Belgium, Switzerland, and the Netherlands). One-fifth of patients reported they have not discussed alternative treatment options with their healthcare professional (HCP) despite 37% of patients being dissatisfied or very dissatisfied with their current therapy. HCPs were considered as the primary information source for the majority of patients (73%), although 27% of patients and 25% of caregivers believed that HCPs were not fully aware of all available treatment options. Moreover, 68% of patients treated with oral antipsychotics confirmed they would consider switching to a long-acting antipsychotic treatment, though 32% reported they have not been made aware of it as an option. Many caregivers (46%) reported dissatisfaction with their level of involvement in treatment decisions.ConclusionsThis survey underlines the critical role HCPs play in providing relevant information on treatment alternatives and emphasize the need for an open dialogue on available treatment options between HCPs, patients and caregivers.Disclosure of interestPierre Cherubin is a full-time Janssen employee working within the Medical Affairs Department.The other authors have not supplied their declaration of competing interest.
Collapse
|
8
|
Schreiner A, Bergmans P, Cherubin P, Hargarter L. The effect of long-acting paliperidone palmitate once-monthly on negative and depressive symptoms in patients with schizophrenia switched from previous unsuccessful treatment with oral aripiprazole. Ther Adv Psychopharmacol 2017; 7:59-65. [PMID: 28255435 PMCID: PMC5315228 DOI: 10.1177/2045125316673012] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND The negative symptoms of schizophrenia are generally harder to recognize, more difficult to treat than positive symptoms, and have a significant impact on patient functioning and overall outcomes. Treatment with aripiprazole may be associated with benefits on negative symptoms and functioning given its partial agonism to the dopamine D2 receptor. The aim of this subanalysis was to explore the impact of flexibly dosed, long-acting paliperidone palmitate once monthly (PP1M) on negative and depressive symptoms, disorganized thoughts, anxiety, extrapyramidal symptoms, and patient functioning in nonacute adult patients with schizophrenia previously unsuccessfully treated with oral aripiprazole monotherapy. METHODS Post-hoc subanalysis of 46 nonacute but symptomatic patients enrolled in a prospective, interventional, single-arm, multicenter, open-label 6-month study. RESULTS At endpoint, improvements of ⩾ 20% and ⩾ 50% in the Positive and Negative Syndrome Scale (PANSS) total score were observed in 52.2% and 21.7% of patients, respectively. Significant and clinically relevant improvements were observed at endpoint in mean (standard deviation [SD]) PANSS negative subscale score (-3.0 (5.0); p < 0.0001) and in the PANSS Marder factor scores for negative symptoms (-2.9 (5.4); p = 0.0006), disorganized thoughts (-2.8 (4.3); p < 0.0001) and anxiety/depression (-1.8 (3.9); p = 0.0031). Patient functioning assessed by mean (SD) Personal and Social Performance scale score (3.9 (13.2); p = 0.0409), Mini International Classification of Functioning rating for Activity and Participation Disorders in Psychological Illnesses total scores (-2.9 (7.1); p = 0.0079), and Extrapyramidal Symptom Rating Scale scores (-0.6 (3.4); p = 0.0456) improved significantly at endpoint. PP1M was well tolerated with no new safety signals. CONCLUSIONS Six-month treatment with flexibly dosed PP1M was associated with significant and clinically relevant improvements in negative and depressive symptoms, disorganized thoughts, functioning, and extrapyramidal symptoms in nonacute but symptomatic patients with schizophrenia previously unsuccessfully treated with oral aripiprazole.
Collapse
Affiliation(s)
- Andreas Schreiner
- Medical and Scientific Affairs, Janssen Cilag EMEA, Johnson & Johnson Platz 1, Neuss, 41470, Germany
| | - Paul Bergmans
- Biometrics, Janssen Cilag Benelux, Tilburg, The Netherlands
| | - Pierre Cherubin
- EMEA Medical Affairs, Janssen Cilag, Issy-les-Moulineaux, France
| | | |
Collapse
|
9
|
Emsley R, Hargarter L, Bergmans P, Uglešić B, Sengül AC, Petralia A, Khannanova A, Cherubin P, Schreiner A. Once-monthly paliperidone palmitate in early stage schizophrenia - a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia. Neuropsychiatr Dis Treat 2017; 13:2261-2269. [PMID: 28919757 PMCID: PMC5587220 DOI: 10.2147/ndt.s142634] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
BACKGROUND Long-acting antipsychotic therapy may be best suited for patients in the early stage of schizophrenia, when the most can be done before disease progression associated with poor adherence occurs. We explored the patterns of use of once-monthly paliperidone palmitate (PP1M), concomitant medication use, hospitalization, and clinical outcomes of adult, newly diagnosed patients with schizophrenia receiving continuous treatment with PP1M for at least 12 months. METHODS This was an international, multicenter, exploratory, retrospective chart review of medical records of adult patients who were newly diagnosed (not more than 1 year before initiation of PP1M treatment) with schizophrenia and who had received continuous treatment with PP1M for ≥12 months in naturalistic clinical settings. RESULTS A total of 84 (93.3%) patients were included in the analysis. All but one patient (98.8%, n=83) had received oral antipsychotic medication at least during the last month before the first PP1M administration. Three patients (3.6%) were newly hospitalized during the 12-month documentation period. The reason for hospitalization for all three was management of episode/relapse. A total of 79.2% of patients had a ≥20% improvement and 47.2% had a ≥50% improvement in Positive and Negative Syndrome Scale total score from baseline to endpoint. Half of patients (53.3%) showed a significant improvement, as reflected by an increase in Personal and Social Performance (PSP) total score of at least 7 points from baseline to endpoint (mean [SD] 11.9 [15.0] points; P<0.001). One quarter of patients (24.4%, n=11) moved from a PSP score of 31-70 (ie, moderate to marked functional impairment) at baseline to a PSP score of mild to no functional impairment (PSP score ≥71) at endpoint. Most adverse drug reactions were mild or moderate in severity. CONCLUSION Continuous treatment with PP1M over 12 months was associated with statistically significant and clinically meaningful improvements in psychotic symptoms, disease severity, and functional outcomes in patients with schizophrenia.
Collapse
Affiliation(s)
- Robin Emsley
- Stellenbosch University, Tygerberg Campus, Cape Town, South Africa
| | | | - Paul Bergmans
- Janssen Cilag, Clinical Biostatistics, Breda, Netherlands
| | - Boran Uglešić
- Department of Psychiatry, University Hospital Centre Split, Split, Croatia
| | | | - Antonino Petralia
- Department of Clinical and Experimental Medicine, School of Medicine, University of Catania, Catania, Italy
| | - Angelina Khannanova
- State Budgetary Healthcare Institution, Psychiatrc Clinical Hospital N3 named after VA Giliarovskiy, Moscow, Russia
| | | | | |
Collapse
|
10
|
Hargarter L, Bergmans P, Cherubin P, Keim S, Conca A, Serrano-Blanco A, Bitter I, Bilanakis N, Schreiner A. Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia. Expert Opin Pharmacother 2016; 17:1043-53. [PMID: 27042990 PMCID: PMC4898156 DOI: 10.1080/14656566.2016.1174692] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Objective: To explore the treatment response, tolerability and safety of once-monthly paliperidone palmitate (PP1M) in non-acute patients switched from oral antipsychotics, stratified by time since diagnosis as recently diagnosed (≤3 years) or chronic patients (>3 years). Research design and methods: Post hoc analysis of a prospective, interventional, single-arm, multicentre, open-label, 6-month study performed in 233 recently diagnosed and 360 chronic patients. Main outcome measures: The proportion achieving treatment response (defined as ≥20% improvement in Positive and Negative Syndrome Scale [PANSS] total score from baseline to endpoint) and maintained efficacy (defined as non-inferiority in the change in PANSS total score at endpoint [Schuirmann’s test]). Results: 71.4% of recently diagnosed and 59.2% of chronic patients showed a ≥20% decrease in PANSS total score (p = 0.0028 between groups). Changes in PANSS Marder factors, PANSS subscales, and the proportion of patients with a Personal and Social Performance scale (PSP) total score of 71–100 were significantly greater in recently diagnosed compared with chronic patients. PP1M was well tolerated, presenting no unexpected safety findings. Conclusion: These data show that recently diagnosed patients treated with PP1M had a significantly higher treatment response and improved functioning, as assessed by the PSP total score, than chronic patients.
Collapse
Affiliation(s)
- L Hargarter
- a Medical & Scientific Affairs , Janssen Cilag EMEA , Neuss , Germany
| | - P Bergmans
- b Biometrics & Reporting , Janssen Cilag Benelux , Tilburg , The Netherlands
| | - P Cherubin
- c Medical Affairs , Janssen Cilag EMEA , Issy-les-Moulineaux , France
| | - S Keim
- d Global Clinical Operations EMEA MAO, Janssen Cilag , Barcarena , Portugal
| | - A Conca
- e Department of Psychiatry , General Hospital , Bolzano , Italy
| | - A Serrano-Blanco
- f Acute Inpatient Unit , Parc Sanitari Sant Joan de Déu , Barcelona , Spain and redIAPP, Spain
| | - I Bitter
- g Department of Psychiatry and Psychotherapy , Semmelweis University , Budapest , Hungary
| | - N Bilanakis
- h Department of Psychiatric , General Hospital of Arta , Arta , Greece
| | - A Schreiner
- a Medical & Scientific Affairs , Janssen Cilag EMEA , Neuss , Germany
| |
Collapse
|
11
|
Schreiner A, Aadamsoo K, Altamura AC, Franco M, Gorwood P, Neznanov NG, Schronen J, Ucok A, Zink M, Janik A, Cherubin P, Lahaye M, Hargarter L. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. Schizophr Res 2015; 169:393-399. [PMID: 26431793 DOI: 10.1016/j.schres.2015.08.015] [Citation(s) in RCA: 96] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/24/2015] [Revised: 08/10/2015] [Accepted: 08/11/2015] [Indexed: 12/11/2022]
Abstract
OBJECTIVE Relapse and acute exacerbation are common in schizophrenia and may impact treatment response and outcome. Evidence is conflicting in respect to superiority of long-acting injectable antipsychotic therapies versus oral antipsychotics in relapse prevention. This randomized controlled study assessed the efficacy of paliperidone palmitate versus oral antipsychotics for relapse prevention. METHOD Eligible patients with a recent diagnosis of schizophrenia (within 1-5 years) were randomized 1:1 to paliperidone palmitate (n=376) or oral antipsychotic monotherapy (n=388) and entered a 2-week initial acute oral treatment phase. Patients who met predefined response criteria were eligible to enter the 24-month rater-blinded core treatment phase. Patients were evaluated for relapse, symptoms, functioning, quality of life, treatment satisfaction, and tolerability. RESULTS In the core treatment phase, time to relapse was significantly longer in the paliperidone palmitate (n=352) compared with the oral antipsychotics arm (n=363): 85% of patients were relapse-free at 469 versus 249 days (P=0.019). Significantly fewer patients receiving paliperidone palmitate met the relapse criteria (52 [14.8%] versus 76 [20.9%, oral antipsychotics]; P=0.032), representing a 29.4% relative risk reduction. For paliperidone palmitate, a significantly greater improvement in Positive and Negative Syndrome Scale total score on Day 8 (P=0.021) and a trend at endpoint (P=0.075) were observed. Functioning improvements were comparable between treatment arms. No new safety signals were identified. CONCLUSION The observed time to relapse superiority of paliperidone palmitate over oral antipsychotics provides further evidence for the value of long-acting injectable antipsychotic therapies in the treatment of schizophrenia, including during the early stages of illness.
Collapse
Affiliation(s)
| | - Kaire Aadamsoo
- North Estonia Medical Centre Foundation, Tallinn, Estonia
| | - A Carlo Altamura
- Department of Psychiatry, University of Milan, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy
| | - Manuel Franco
- Psychiatric Department, Zamora Hospital, Zamora, Spain
| | - Philip Gorwood
- Hôpital Sainte-Anne, Paris Descartes University (INSERM U894), France
| | - Nikolaj G Neznanov
- St Petersburg V.M. Bekhterev Psychoneurological Research Institute, St Petersburg, Russia
| | | | - Alp Ucok
- Istanbul Medical Faculty, Istanbul, Turkey
| | - Mathias Zink
- Central Institute of Mental Health, Department of Psychiatry and Psychotherapy, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Adam Janik
- Global Clinical Operations, Janssen-Cilag, Warsaw, Poland
| | - Pierre Cherubin
- Medical Affairs, Janssen Cilag EMEA, Issy-les-Moulineaux, France
| | | | | |
Collapse
|
12
|
Emsley R, Alptekin K, Azorin JM, Cañas F, Dubois V, Gorwood P, Haddad PM, Naber D, Olivares JM, Papageorgiou G, Roca M, Thomas P, Hargarter L, Schreiner A. Nurses' perceptions of medication adherence in schizophrenia: results of the ADHES cross-sectional questionnaire survey. Ther Adv Psychopharmacol 2015; 5:339-50. [PMID: 26834967 PMCID: PMC4722504 DOI: 10.1177/2045125315612013] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
OBJECTIVES Poor adherence to antipsychotic treatment is a widespread problem within schizophrenia therapy with serious consequences including increased risks of relapse and rehospitalization. Mounting evidence supports the key roles that nurses play in monitoring patient progress and facilitating long-term treatment adherence. The Adherencia Terapéutica en la Esquizofrenia (ADHES) nurses' survey was designed to assess the opinions of nurses on the causes and management of partial/nonadherence to antipsychotic medication. METHODS A questionnaire-based cross-sectional survey of 4120 nurses from Europe, the Middle East and Africa. Interpretation of results was based on a descriptive comparison of responses. RESULTS Nurses perceived 54% of patients seen in the preceding month to be partially/nonadherent to treatment. Most nurses (90%) reported some level of experience with administration of long-acting injectable (LAI) antipsychotics, with 24% of nurses administering >10 injections per month. The majority (85%) of nurses surveyed believed that improving adherence would improve patient outcomes. Nearly half (49%) reported that most of their patients depend on a family member or other nonprofessional carer to remind them to take their medication as prescribed. A similar proportion of nurses (43%) reported that most of their patients relied on a professional to remind them to take medication. Most nurses (92%) felt that ensuring continuous medication with LAI antipsychotics would yield long-term benefits for patients, but their opinion was that over a third of patients were unaware of LAI antipsychotic treatments. In a series of forced options, the strategy used most often by respondents (89%) to promote medication adherence was to build trusting relationships with patients while listening to and interpreting their needs and concerns. Respondents also rated this as the most effective strategy that they used (48%). CONCLUSION Nurses are highly aware of adherence issues faced by their patients; further patient education on treatment options is needed.
Collapse
Affiliation(s)
- Robin Emsley
- Department of Psychiatry, University of Stellenbosch, Tygerberg 7505, Cape Town, South Africa
| | - Koksal Alptekin
- Department of Psychiatry, Dokuz Eylül University School of Medicine, Izmir, Turkey
| | | | - Fernando Cañas
- Department of Psychiatry, Hospital Dr R Lafora, Cra de Colmenar Viejo, Madrid, Spain
| | - Vincent Dubois
- Service de psychiatrie adulte, Cliniques universitaires St-Luc, Bruxelles, Belgium
| | - Philip Gorwood
- CMME, Hôpital Sainte-Anne (Paris Descartes), Paris, France
| | - Peter M Haddad
- Greater Manchester West Mental Health NHS Foundation Trust and Department of Psychiatry, University of Manchester, Manchester, UK
| | - Dieter Naber
- Klinik für Psychiatrie und Psychotherapie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
| | - José Manuel Olivares
- Department of Psychiatry, Hospital Meixoeiro, Complejo Hospitalario Universitario de Vigo, Vigo, Spain
| | | | - Miguel Roca
- Unidad de Psiquiatría, Hospital Juan March, Institut Universitari d'Investigació en Ciències de la Salut (IUNICS), Universitat de les Illes Balears, Palma de Mallorca, Spain
| | - Pierre Thomas
- Service de Psychiatrie, Hôpital M. Fontan, Lille, France
| | - Ludger Hargarter
- Department of Medical and Scientific Affairs, Janssen EMEA, Neuss, Germany
| | - Andreas Schreiner
- Department of Medical and Scientific Affairs, Janssen EMEA, Neuss, Germany
| | | |
Collapse
|
13
|
Schreiner A, Bergmans P, Cherubin P, Hargarter L. Effets du palmitate de palipéridone sur les symptômes négatifs, la dépression/anxiété, le fonctionnement et les symptômes extrapyramidaux chez des patients souffrant d’une schizophrénie non-aiguë, en échec du traitement par aripiprazole oral. Eur Psychiatry 2015. [DOI: 10.1016/j.eurpsy.2015.09.303] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
Abstract
ObjectifÉvaluer l’effet du palmitate de palipéridone (PP) à doses flexibles sur les symptômes négatifs, la dépression/anxiété, le fonctionnement et les symptômes extrapyramidaux chez des patients adultes souffrant de schizophrénie non-aiguë, en échec à un traitement par aripiprazole oral.MéthodesÉtude internationale, prospective, en ouvert de 6 mois.ÉvaluationsVariations entre début d’étude (baseline) et dernière observation rapportée sur la PANSS (Positive and Negative Syndrome Scale), la sous-échelle négative de la PANSS, les facteurs de Marder de la PANSS « symptômes négatifs » et « anxiété/dépression », les échelles de fonctionnement PSP (Personal and Social Performance) et Mini-ICF (Mini International Classification of Functioning) et l’échelle ESRS (Extrapyramidal Symptom Rating Scale).RésultatsQuarante-six patients analysés (73,9 % hommes, âge moyen 34,4 ± 9,4 ans, 78,3 % schizophrénie paranoïde). Parmi les patients, 67,4 % ont terminé l’étude. Avant l’inclusion, la dose moyenne d’aripiprazole oral était de 22,7 ± 10,7 mg/jour. Le score de la sous-échelle négative de PANSS s’est significativement amélioré de 20,3 ± 5,0 (baseline) à 17,3 ± 6,1 (fin d’étude) (variation moyenne = −3,0 ± 5,0 ; IC 95 % = −4,4 ; −1,5 ; p < 0,0001), ainsi que les scores des facteurs de Marder « symptômes négatifs » (de 19,5 ± 5,8 à 16,6 ± 5,9 ; IC95 % = −4,5 ; −1,3, p < 0,0001) et « anxiété/dépression » (de 10,3 ± 3,6 à,5 ± 2,9 ; IC95 % = −3,0 ; −0,6, p = 0,0031). Le score ESRS s’est aussi amélioré de manière significative (de −0,6 ± 3,4 ; IC 95 % = −1,6 ; 0,4, p = 0,0456). Le fonctionnement du patient s’est amélioré de manière significative sur les échelles PSP (de 58,9 ± 13,4 à 62,9 ± 15,2, p = 0,041) et Mini-ICF (de 19,0 ± 7,78 à 16,1 ± 9,84 ; IC 95 % −5,1, −0,7 ; p = 0,0079). Le seul événement indésirable sous traitement rapporté chez ≥ 5 patients a été l’anxiété (n = 6).ConclusionsLa transition d’un échec au traitement par aripiprazole oral à un traitement par PP à doses flexibles chez des patients souffrant de schizophrénie non-aiguë a été bien tolérée et s’est traduit par une amélioration significative des symptômes négatifs, dépressifs, anxieux et des symptômes extrapyramidaux, ainsi que du fonctionnement du patient.Traduction de l’abstract résumé présenté au congrès EPA 2015 (European Congress of Psychiatry, Vienna, Austria, 28–31 March 2015)
Collapse
|
14
|
Svettini A, Johnson B, Magro C, Saunders J, Jones K, Silk S, Hargarter L, Schreiner A. Schizophrenia through the carers' eyes: results of a European cross-sectional survey. J Psychiatr Ment Health Nurs 2015; 22:472-83. [PMID: 25944551 DOI: 10.1111/jpm.12209] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 02/05/2015] [Indexed: 01/30/2023]
Abstract
Schizophrenia is a serious mental disorder affecting approximately 29 million people worldwide. The ideal treatment and care of patients with schizophrenia should be provided by a multidisciplinary 'team' involving psychiatrists, nurses and other healthcare professionals, together with carers and patients. In light of the key role carers play in the care of patients with schizophrenia, the present survey was designed to assess the opinions of family members and friends of patients with schizophrenia across Europe and to ascertain their attitudes towards the illness, medication and adherence to medication. Among carers participating in this survey, there was widespread awareness of the issues involved in supporting patients with schizophrenia and the importance of their role in improving poor adherence to medication. Three differences in opinion emerged between the views of carers and psychiatrists; psychiatrists rely more on the patient themselves when assessing adherence than carers would recommend; in contrast to psychiatrists, many carers believe the illness itself contributes to non-adherence; two thirds of carers think that schizophrenia medication damages health (higher than estimated by psychiatrists). The findings from the present survey, taken together with the results from the Adherencia Terapéutica en la Esquizofrenia surveys of psychiatrists and nurses, support the need for a collaborative approach to the issue of treatment nonadherence. In particular, healthcare professionals should recognize the valuable contribution that family carers can make to improve treatment adherence and consequently clinical outcomes for patients with schizophrenia. Schizophrenia carries a significant burden for families providing care. The Adherencia Terapéutica en la Esquizofrenia (ADHES) carers' survey was designed to assess the opinions of family and friends of patients with schizophrenia across Europe and ascertain their attitudes towards the illness, medication and adherence to medication. A questionnaire-based cross-sectional survey of 138 carers across 16 European countries. Interpretation of results was based on a descriptive comparison of responses. Carers recognized the importance of medication to help patients get better (76%) and improve their quality of life (76%) and relationships (74%). Sixty-seven per cent believed medication damages general health. Sixty-five per cent reported that treatment adherence was a burden for patients. Thirty-eight per cent indicated that it was a daily struggle to get patients to take their medication. Fifty per cent perceived that medication administered every few weeks rather than daily was quite/very important. Ninety-three per cent agreed on the importance of family support to boost adherence, with education and information deemed important for families and patients. Carers rely less on the patient themselves when assessing adherence than psychiatrists. The burden faced by carers and patients in taking medication provides an opportunity for healthcare professionals to provide support in a multidisciplinary 'team' involving psychiatrists, nurses and carers.
Collapse
Affiliation(s)
| | | | | | | | | | - S Silk
- Communication & Public Affairs, Janssen EMEA, High Wycombe, UK
| | - L Hargarter
- European Medical Affairs, Janssen EMEA, Neuss, Germany
| | - A Schreiner
- Medical and Scientific Affairs, Janssen EMEA, Neuss, Germany
| |
Collapse
|
15
|
Schreiner A, Bergmans P, Cherubin P, Keim S, Llorca PM, Cosar B, Petralia A, Corrivetti G, Hargarter L. Paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics. J Psychopharmacol 2015; 29:910-22. [PMID: 25999398 PMCID: PMC4512527 DOI: 10.1177/0269881115586284] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/03/2022]
Abstract
PALMFlexS, a prospective multicentre, open-label, 6-month, phase IIIb interventional study, explored tolerability, safety and treatment response in adults (n = 231) with non-acute but symptomatic schizophrenia switching to flexibly dosed paliperidone palmitate (PP) after unsuccessful treatment with risperidone long-acting injectable therapy (RLAT) or conventional depot antipsychotics (APs). Treatment response was measured by change in Positive and Negative Syndrome Scale (PANSS) total score from baseline (BL) to last-observation-carried-forward (LOCF) endpoint (EP). Safety and tolerability assessments included Extrapyramidal Symptom Rating Scale (ESRS) total score and treatment-emergent adverse events. Significant reductions in mean PANSS total score were observed for all groups (-7.5 to -10.6; p ⩽ 0.01 [BL to LOCF EP]). After switching to PP, more than 50% of all patients achieved ⩾20% and one-third of RLAT-treated patients even achieved ⩾50% improvement in PANSS total score. Across groups, there were significant improvements (p < 0.05) in symptom severity as measured by Clinical Global Impression-Severity (CGI-S; trend for improvement with RLAT; p = 0.0568), subjective well-being, medication satisfaction, and patient functioning with PP. PP was generally well tolerated. Clinically relevant benefits were observed in non-acute patients with schizophrenia switched from RLAT or conventional depot APs to PP.
Collapse
Affiliation(s)
- A Schreiner
- EMEA Medical Affairs, Janssen Cilag GmbH, Neuss, Germany
| | - P Bergmans
- Biometrics & Reporting, Janssen Cilag Benelux, Tilburg, the Netherlands
| | - P Cherubin
- EMEA Medical Affairs, Janssen Cilag, Issy-les-Moulineaux, France
| | - S Keim
- Global Clinical Operations EMEA Medical Affairs, Janssen Cilag, Barcarena, Portugal
| | - P-M Llorca
- CHRU Clermont-Ferrand, Hôpital Gabriel Montpied, Clermont-Ferrand, France
| | - B Cosar
- Gazi University Medical Faculty, Ankara, Turkey
| | - A Petralia
- UOPI of Psychiatry, AOU Policlinico Vittorio Emanuele, Catania, Italy
| | - G Corrivetti
- UOSM Distretto D, Pontecagnano-Faiano (Sa), Italy
| | - L Hargarter
- EMEA Medical Affairs, Janssen Cilag GmbH, Neuss, Germany
| |
Collapse
|
16
|
Hargarter L, Cherubin P, Bergmans P, Keim S, Rancans E, Bez Y, Parellada E, Carpiniello B, Vidailhet P, Schreiner A. Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2015; 58:1-7. [PMID: 25448776 DOI: 10.1016/j.pnpbp.2014.11.006] [Citation(s) in RCA: 48] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/03/2014] [Revised: 10/28/2014] [Accepted: 11/10/2014] [Indexed: 11/26/2022]
Abstract
In this prospective multicentre, open-label, 6-month study (Paliperidone Palmitate Flexible Dosing in Schizophrenia [PALMFlexS]), tolerability, safety and treatment response with paliperidone palmitate (PP) were explored in patients with acute symptoms of schizophrenia following switching from previously unsuccessful treatment with oral antipsychotics. This pragmatic study was conducted in a large, more representative sample of the general schizophrenia population compared to randomized controlled pivotal trials, to specifically mimic real-world clinical situations. After initiation on Day 1 and Day 8, patients received PP once monthly at flexible doses (50-150mgeq.) intramuscularly. The primary efficacy outcome was defined as the percentage of patients achieving ≥30% improvement in PANSS total score from baseline (BL) to last-observation-carried-forward (LOCF) endpoint (EP). Safety and tolerability assessments included Extrapyramidal Symptom Rating Scale (ESRS) total score and treatment-emergent adverse events (TEAEs). Overall, 212 patients received PP at least once after switching from oral antipsychotics, primarily due to lack of efficacy (45.8%). Significant improvements from BL in mean (SD) PANSS total score were observed from Day 8 onwards (BL to LOCF EP: -31.0 [29.0]; p<0.0001). At endpoint, two-thirds (66.7%) and 43.5% of patients achieved a ≥30% and ≥50% improvement in mean PANSS total score, respectively. PP was associated with significant improvements across secondary measures of symptom severity, subjective well-being, medication satisfaction, illness-related disorders of activity and participation, and patient functioning (p<0.0001; BL to LOCF EP). PP was generally well tolerated, with significant reductions in ESRS total score (p<0.0001) and mainly mild-to-moderate TEAEs. TEAEs reported in ≥5% of patients were injection-site pain (13.7%), insomnia (10.8%), psychotic disorder (10.4%), headache and anxiety (both 6.1%). The PALMFlexS study findings provide valuable pragmatic clinical data on PP treatment in patients with acute schizophrenia previously unsuccessfully treated with oral antipsychotics.
Collapse
Affiliation(s)
- Ludger Hargarter
- Medical & Scientific Affairs, Janssen Cilag EMEA, Neuss, Germany.
| | - Pierre Cherubin
- Medical Affairs, Janssen Cilag EMEA, Issy-les-Moulineaux, France
| | - Paul Bergmans
- Biometrics and Reporting, Janssen Cilag Benelux, Tilburg, The Netherlands
| | - Sofia Keim
- Global Clinical Operations EMEA MAO, Janssen Cilag, Barcarena, Portugal
| | - Elmars Rancans
- Department of Psychiatry and Narcology, Riga Stradins University, Riga, Latvia
| | - Yasin Bez
- Dicle University Medical Faculty, Diyarbakir, Turkey
| | - Eduard Parellada
- Barcelona Clinic Schizophrenia Unit (BCSU), Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain
| | | | - Pierre Vidailhet
- Centre Hospitalier Régional Universitaire de Strasbourg, Strasbourg, France
| | | |
Collapse
|
17
|
Schreiner A, Bergmans P, Cherubin P, Hargarter L. Paliperidone Palmitate – Effect On Negative, Depression/anxiety, Patient Functioning and Extrapyramidal Symptoms in Non-acute Schizophrenia Patients Previously Unsuccessfully Treated with Oral Aripiprazole. Eur Psychiatry 2015. [DOI: 10.1016/s0924-9338(15)30711-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
18
|
Hargarter L, Lahaye M, Cherubin P, Schreiner A. Tolerability, Safety and Treatment Response of Flexibly-dosed Paliperidone Palmitate in Patients Hospitalized for an Exacerbation of Schizophrenia. Eur Psychiatry 2015. [DOI: 10.1016/s0924-9338(15)30710-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
19
|
Schreiner A, Hargarter L, Hitschfield K, Lee JI, Lenskaya I, Sulaiman AH, Diels J. Clinical effectiveness and resource utilization of paliperidone ER for schizophrenia: Pharmacoepidemiologic International Longitudinal Antipsychotic Registry (PILAR). Curr Med Res Opin 2014; 30:1279-89. [PMID: 24597755 DOI: 10.1185/03007995.2014.898630] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
OBJECTIVE To document prescribing patterns in clinical practice and assess long-term outcomes related to initiation of paliperidone ER and other oral antipsychotics among patients with schizophrenia in a naturalistic setting. RESEARCH DESIGN AND METHODS An international, non-interventional, naturalistic study of adult patients (≥18 years) with schizophrenia. Patients were assigned to the relevant treatment group (paliperidone ER or 'all other oral antipsychotics') after switching to, or initiating, oral antipsychotic treatment. Retrospective 12 month data collection was followed by 12 month prospective data collection, with 3-monthly assessments. The primary endpoint was time to all-cause discontinuation of new medication. Secondary endpoints included Clinical Global Impression-Severity (CGI-S) score, Clinical Global Impression-Schizophrenia (CGI-SCH) score, Personal and Social Performance (PSP) score, health-related quality of life (HR-QoL) and quality of sleep, evaluation of healthcare resource utilization and patient's treatment satisfaction. RESULTS A total of 4051 patients were included in the intent-to-treat (ITT) analysis set. All-cause study discontinuation rates were comparable between the paliperidone ER group (16.8%) and the 'all other oral antipsychotics' group (15.5%). There was no difference in the time to discontinuation of newly initiated antipsychotic treatments between paliperidone ER and 'all other oral antipsychotics' groups. Paliperidone ER was associated with greater improvements from baseline to endpoint in both the PSP scale score (+14.2 vs +13.1, p = 0.041) and the physical component of quality of life (SF-12 Physical scores; +3.9 vs +2.9, p = 0.003) compared to 'all other oral antipsychotics'. Improvements in mean CGI-S score, CGI-SCH score, HR-QoL, quality of sleep and daytime drowsiness, as well as patients' treatment satisfaction were comparable between treatment groups. The incidence of adverse events was comparable between groups. CONCLUSIONS This study provides valuable data on the prescribing habits and treatment outcomes associated with use of paliperidone ER in everyday clinical practice, and supports previous findings of the favorable functional improvement and treatment satisfaction associated with paliperidone ER. CLINICAL TRIAL REGISTRATION NCT00696813; R076477SCH4015 (Register of German Association of Research-based Pharmaceutical Companies [VFA] http://www.vfa.de/de/arzneimittel-forschung/datenbanken-zu-arzneimitteln/nisdb).
Collapse
|
20
|
Hargarter L, Bergmans P, Cherubin P, Björner A, Knegtering R, Parellada E, Carpiniello B, Vidailhet P, Mertens C, Schreiner A. EPA-1545 - Functional outcomes with once-monthly paliperidone palmitate in acute and in non-acute patients with schizophrenia previously unsuccessfully treated with oral antipsychotics. Eur Psychiatry 2014. [DOI: 10.1016/s0924-9338(14)78709-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
21
|
Hargarter L, Bergmans P, Cherubin P, Rancans E, Bez Y, Parellada E, Carpiniello B, Vidailhet P, Schreiner A. EPA-1547 - Once monthly paliperidone palmitate – tolerability and treatment response in recently diagnosed versus chronic non-acute schizophrenia patients switched from previously unsuccessful treatment with oral antipsychotics. Eur Psychiatry 2014. [DOI: 10.1016/s0924-9338(14)78711-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
22
|
Schreiner A, Aadamsoo K, Altamura A, Franco M, Goorwood P, Neznanov N, Schronen J, Ucok A, Zink M, Cherubin P, Lahaye M, Hargarter L. EPA-1549 - A randomized, active-controlled rater-blinded 2-year study of paliperidone palmitate versus investigators’ choice of oral antipsychotic monotherapy in patients with schizophrenia (prosipal). Eur Psychiatry 2014. [DOI: 10.1016/s0924-9338(14)78713-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
23
|
Hargarter L, Bergmans P, Cherubin P, Rancans E, Bez Y, Parellada E, Carpiniello B, Vidailhet P, Schreiner A. EPA-1546 - Paliperidone palmitate in non-acute but symptomatic patients with schizophrenia previously unsuccessfully treated with oral aripiprazole. Eur Psychiatry 2014. [DOI: 10.1016/s0924-9338(14)78710-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
24
|
Schreiner A, Bergmans P, Cherubin P, Rancans E, Bez Y, Parellada E, Carpiniello B, Vidailhet P, Hargarter L. EPA-1550 - Paliperidone palmitate in acute patients with schizophrenia: treatment response, safety and tolerability ? a prospective flexible-dose study in patients previously unsuccessfully treated with oral antipsychotics. Eur Psychiatry 2014. [DOI: 10.1016/s0924-9338(14)78714-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
25
|
Schreiner A, Hargarter L, Bergmans P, Cherubin P, Rancans E, Bez Y, Parellada E, Carpiniello B, Vidailhet P. EPA-1551 - Paliperidone palmitate – impact on negative, disorganized and depressive symptoms, subjective well-being and patient satisfaction in patients with schizophrenia previously unsuccessfully treated with oral antipsychotics. Eur Psychiatry 2014. [DOI: 10.1016/s0924-9338(14)78715-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
26
|
Hargarter L, Bergmans P, Cherubin P, Rancans E, Bez Y, Parellada E, Carpiniello B, Vidailhet P, Schreiner A. EPA-1548 - Flexibly dosed paliperidone palmitate in non-acute patients with schizophrenia switched from previously unsuccessful monotherapy with oral atypical antipsychotics. Eur Psychiatry 2014. [DOI: 10.1016/s0924-9338(14)78712-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
27
|
Schreiner A, Hargarter L, Llorca P, Cosar B, Petralia A, Bergmans P, Cherubin P. EPA-1553 - Flexibly dosed paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with conventional depot antipsychotics. Eur Psychiatry 2014. [DOI: 10.1016/s0924-9338(14)78717-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
28
|
Hargarter L, Bergmans B, Cherubin P, Bjorner A, Knegtering H, Parellada E, Carpiniello B, Vidailhet P, Mertens C, Schreiner A. Amélioration fonctionnelle sous palmitate de paliperidone à doses flexibles chez des patients aigus ou non aigus atteints de schizophrénie, après échec d’un traitement par antipsychotiques oraux. Eur Psychiatry 2013. [DOI: 10.1016/j.eurpsy.2013.09.288] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
Abstract
ObjectifsÉvaluer l’amélioration fonctionnelle chez des patients atteints de schizophrénie sous palmitate de paliperidone (PP) à doses flexibles après échec d’un traitement par antipsychotiques oraux.MéthodesAnalyse menée dans deux sous-groupes de patients atteints de schizophrénie : aigus (n = 202) et non aigus (n = 593) après échec d’un traitement par antipsychotiques oraux, inclus dans une étude internationale, prospective, de six mois.Critères d’évaluationChangement du score total à la PANSS (Positive and Negative Syndrome Scale), à la PSP (Personal and Psychosocial Performance scale), et à la Mini-ICF-APP (Mini International Classification of Functionality, Disability and Health Rating for Activity and Participation Disorders in Psychological Illnesses).RésultatsLes deux sous-groupes ont présenté une amélioration significative du score total à la PANSS : de 98,5 ± 20,1 à l’inclusion à 67,4 ± 24,0 à la fin de l’étude (diminution moyenne = −31,0 ± 29,0) chez les patients aigus et de 71,5 ± 14,6 à 59,7 ± 18,1 (diminution moyenne = −11,7 ± 15,9) chez les patients non aigus. Cette réponse thérapeutique était associée à une augmentation significative du score total à la PSP de 43,9 ± 15,0 à 62,9 ± 17,1 (amélioration moyenne = 19,0 ± 18,7, p <0,0001) chez les patients aigus, et de 58,1 ± 13,4 à 66,1 ± 15,7 (amélioration moyenne =8,0 ± 14,0, p < 0,0001) chez les patients non aigus. Il existait une amélioration significative du score à la Mini-ICF-APP qui diminuait de 26,8 ± 8,5 à 18,5 ± 9,8 (diminution moyenne = −8,0 ± 10,4, p < 0,0001) chez les patients aigus et de 19,8 ± 7,9 à 15,9 ± 8,8 (diminution moyenne = −4,0 ± 7,5, p < 0,0001) chez les patients non aigus.ConclusionsL’amélioration symptomatique sous PP à doses flexibles chez des patients aigus ou non-aigus atteints de schizophrénie après échec d’un traitement par antipsychotique oral s’est accompagnée d’une amélioration fonctionnelle cliniquement significative.
Collapse
|
29
|
Hargarter L, Bergmans P, Cherubin P, Schreiner A. Safety, tolerability and treatment response with flexible doses of paliperidone palmitate in patients with an acute exacerbation of schizophrenia. Pharmacopsychiatry 2013. [DOI: 10.1055/s-0033-1353264] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
30
|
Gorwood P, Burns T, Juckel G, Rossi A, San L, Hargarter L, Schreiner A. Psychiatrists' perceptions of the clinical importance, assessment and management of patient functioning in schizophrenia in Europe, the Middle East and Africa. Ann Gen Psychiatry 2013; 12:8. [PMID: 23531356 PMCID: PMC3778848 DOI: 10.1186/1744-859x-12-8] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/17/2013] [Accepted: 02/27/2013] [Indexed: 12/02/2022] Open
Abstract
BACKGROUND It has been estimated that as many as two thirds of patients with schizophrenia are unable to perform basic personal and social roles or activities. Occupational functioning and social functioning, as well as independent living, are considered as core domains of patient functioning. Improvement in patient functioning has also been recognized as an important treatment goal in guidelines and an important outcome by regulatory agencies. Nevertheless, information is lacking on how these aspects are being considered by psychiatrists across the world and how they are being assessed and managed. METHODS The 'Europe, the Middle East and Africa functioning survey' was designed to canvas opinions of psychiatrists across these regions to ascertain their perceptions of the clinical importance, assessment and management of functioning amongst their patients with schizophrenia. The survey comprised 17 questions and was conducted from March to April 2011 in 42 countries. Data collected included the demographics of respondents and their opinions regarding personal and social functioning in patients with schizophrenia. RESULTS Results were obtained from 4,163 clinicians. Psychiatrists estimated that more than two thirds (70%) of their patients with schizophrenia showed impaired or very poor levels of functioning. The majority of psychiatrists (92%) believed that personal and social functioning was an important treatment goal for patients with schizophrenia, and 91% believed it was an important goal for patients' families. The majority of psychiatrists (55%) assess the personal and social functioning of their patient at each visit; however, 81% reported that they determine the level of functioning through clinical interview and not by using a specific assessment scale. To manage personal and social functioning in their patients, 26% of psychiatrists prefer pharmacological interventions, whereas 46% prefer psychosocial interventions. CONCLUSION Psychiatrists recognize that functioning is impaired/very poor in patients with schizophrenia, and there is still an important need to address functioning as a main treatment goal for patients with schizophrenia.
Collapse
Affiliation(s)
- Philip Gorwood
- CMME, Sainte-Anne Hospital, Paris-Descartes University, 100 rue de la
Santé, Paris, Cedex 14, 75674, France
- INSERM UMR894, Centre of Psychiatry and Neuroscience, 2ter rue d'Alesia,
Paris 75014, France
| | - Tom Burns
- Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford,
OX3 7JX, UK
| | - Georg Juckel
- Psychiatrie, LWL-Universitaetsklinikum der Ruhr-Universitaet Bochum, Bochum,
44791, Germany
| | - Alessandro Rossi
- Department of Experimental Medicine, University de L'Aquila, Coppito II,
L'Aquila, 67100, Italy
| | - Luis San
- Hospital Sant Joan de Déu, Centro de Investigación Biomédica
en Red de Salud Mental (CIBERSAM), Passeig Sant Joan de Déu 2,
Esplugues de Llobregat, Barcelona, 08950, Spain
| | - Ludger Hargarter
- Department of Medical and Scientific Affairs, Janssen EMEA, Johnson &
Johnson Platz 1, Neuss, 41470, Germany
| | - Andreas Schreiner
- Department of Medical and Scientific Affairs, Janssen EMEA, Johnson &
Johnson Platz 1, Neuss, 41470, Germany
| |
Collapse
|
31
|
Schreiner A, Hargarter L, Bergmans P, Cherubin P. 1096 – Safety, tolerability and treatment response with flexible doses of paliperidone palmitate in non-acute patients with schizophrenia. Eur Psychiatry 2013. [DOI: 10.1016/s0924-9338(13)76203-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
32
|
Schreiner A, Hargarter L, Bergmans P, Cherubin P. 1100 – Safety, tolerability and treatment response with flexible doses of paliperidone palmitate in patients with an acute exacerbation of schizophrenia. Eur Psychiatry 2013. [DOI: 10.1016/s0924-9338(13)76206-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
33
|
Gorwood P, Juckel G, Burns T, Rossi A, San L, Cherubin P, Hargarter L, Schreiner A. P-1243 - Psychiatrists' perceptions of the clinical importance, assessment and management of functioning: results of the EMEA survey in schizophrenia. Eur Psychiatry 2012. [DOI: 10.1016/s0924-9338(12)75410-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
34
|
Svettini A, Johnson B, Magro C, Saunders J, Jones K, Silk S, Hargarter L, Schreiner A. P-1242 - Schizophrenia through the carers’ eyes: results of a european survey. Eur Psychiatry 2012. [DOI: 10.1016/s0924-9338(12)75409-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
35
|
Hargarter L, Diekamp B, Ibach B, Juckel G. P03-44 - Effectiveness of long-acting injectable risperidone in the post-acute treatment of schizophrenic patients in ambulatory care. Eur Psychiatry 2010. [DOI: 10.1016/s0924-9338(10)71154-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
36
|
Juckel G, Diekamp B, Ibach B, Hargarter L. P03-45 - Psychosocial functioning of schizophrenic patients in post-acute treatment with long-acting injectable risperidone in ambulatory care. Eur Psychiatry 2010. [DOI: 10.1016/s0924-9338(10)71155-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
37
|
Schreiner A, Ibach B, Hargarter L, Diekamp B. PW01-178 - Effectiveness, tolerability and compliance of schizophrenic patients under treatment with oral atypical antipsychotics or long-acting injectable risperidone in daily routine. Eur Psychiatry 2010. [DOI: 10.1016/s0924-9338(10)71585-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
38
|
Juckel G, Schaub D, Fuchs N, Naumann U, Uhl I, Witthaus H, Hargarter L, Bierhoff HW, Brüne M. Validation of the Personal and Social Performance (PSP) Scale in a German sample of acutely ill patients with schizophrenia. Schizophr Res 2008; 104:287-93. [PMID: 18595665 DOI: 10.1016/j.schres.2008.04.037] [Citation(s) in RCA: 77] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/26/2008] [Revised: 04/20/2008] [Accepted: 04/28/2008] [Indexed: 11/19/2022]
Abstract
In trying to more broadly define outcome in the efficient long-term treatment of patients with schizophrenia it is necessary to consider not only a reduction in psychopathological symptoms but also a successful psychosocial reintegration. Thus, a more exact assessment of psychosocial functioning is needed. Since the GAF (Global Assessment of Functioning) scale and the SOFAS (Social and Occupational Functioning Assessment Scale) are less operationalized and confuse psychosocial facts with psychopathological symptoms, the Personal and Social Performance (PSP) scale was developed [Morosini, P.L., Magliano, L., Brambilla, L., Ugolini, S., Pioli, R. (2000). Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatrica Scandinavica, 1001, 323-329.] containing the four main areas "socially useful activities, personal and social relationships, self-care, as well as disturbing and aggressive behaviour". Validation of the PSP scale was conducted in a sample of 62 patients with acute schizophrenia. Rating instruments were PSP, GAF, SOFAS, PANSS, CGI, and Mini-ICF-P (Mini-ICF-Rating for Mental Disorders). The results showed good reliability with alpha=.64-.84, high test-retest reliability as well as good inter-rater reliability for the PSP scale. Furthermore, PSP proved good validity with high correlations to GAF (r=.91), SOFAS (r=.91), and Mini-ICF-P (r=-.69). The hypothesis that more critically ill patients would show lower scores on PSP than lesser ill patients was only confirmed for PANSS negative symptoms. Thus, the findings prove the PSP scale to be a reliable and valid instrument for assessing social functioning of patients with schizophrenia during the course of treatment as well as in the acute state.
Collapse
Affiliation(s)
- Georg Juckel
- Department of Psychiatry, Ruhr University Bochum, LWL Hospital, Germany.
| | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Mitt C, Arend W, Schauble B, Hargarter L, Mattejat F. Changes in quality of life in ADHD-patients treated with extended-release Methylphenidate (OROS®-MPH) - results from an open-label naturalistic study. Eur Psychiatry 2008. [DOI: 10.1016/j.eurpsy.2008.01.1364] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
40
|
Adam A, Haertling F, Bogdanow M, Mattejat F, Hargarter L, Schauble B. OROS®-MPH in adolescents with ADHD transitioning from Atomoxetine or ER-MPH (medikinet retard®) - a post-hoc analysis. Eur Psychiatry 2008. [DOI: 10.1016/j.eurpsy.2008.01.1363] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
41
|
Kordon A, Ancker U, Schlueter D, Hargarter L, Mattejat F, Schauble B. Treatment with OROS®-Methylphenidate in adolescents is associated with an improvement in functioning and quality of life - A post-hoc analysis. Eur Psychiatry 2008. [DOI: 10.1016/j.eurpsy.2008.01.1325] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
42
|
Meltzer H, Hargarter L, Kramer M, Sherr J, Gassmann-Mayer C, Lim P, Bobo W, Eerdekens M. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week placebo-controlled studies (PAL-SCH-303/304/305). Pharmacopsychiatry 2007. [DOI: 10.1055/s-2007-991757] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
43
|
Ibach B, Gerwe M, Hargarter L, Czekalla J. Evaluating decision criteria for the choice of pharmacological long-term therapy in risperidone treated patients with schizophrenia. Pharmacopsychiatry 2007. [DOI: 10.1055/s-2007-991759] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
44
|
Vermeir M, Boom S, Naessens I, Talluri K, Eerdekens M, Hargarter L. Absorption; metabolism and excretion of a single oral dose of 14c-paliperidone 1mg in healthy subjects (PAL-053). Pharmacopsychiatry 2007. [DOI: 10.1055/s-2007-991778] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
45
|
Karlsson P, Hargarter L, Dencker E, Nyberg S, Mannaert E, Boom S, Talluri K, Rossenu S, Eriksson B, Eerdekens M, Farde L. Pharmacokinetics and dopamine d2 and serotonin 5-ht2a receptor occupancy of paliperidone in healthy subjects: two open-label, single-dose studies (PAL-115). Pharmacopsychiatry 2007. [DOI: 10.1055/s-2007-991781] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
46
|
Ibach B, Hargarter L, Gerwe M, Czekalla J. Time to clincal stabilization of in-patients with schizophrenia after conversion to long-acting risperidone. Pharmacopsychiatry 2007. [DOI: 10.1055/s-2007-991760] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
47
|
Czekalla J, Ibach B, Gerwe M, Klose N, Hargarter L, Schreiner A. Interim analysis of 2-years non-interventional trial (LARA) shows tendency towards higher treatment adherence with less compliant schizophrenia patients under long-acting injectable risperidone (LAIR) compared to an oral atypicals (OA) treatment cohort. Pharmacopsychiatry 2007. [DOI: 10.1055/s-2007-991745] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
48
|
Kramer M, Hargarter L, Kushner S, Sherr J, Vijapurkar U, Lim P, Eerdekens M. Delaying symptom recurrence in patients with schizophrenia with paliperidone extended-release tablets: an international, randomized, double-blind, placebo-controlled study (PAL-SCH-301). Pharmacopsychiatry 2007. [DOI: 10.1055/s-2007-991776] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
49
|
Klose N, Gerwe M, Hargarter L, Czekalla J, Mattejat F. Quality of life of children with ADHD – prospective, multicenter non-interventional LECO-trial evaluating the impact on QOL, effectiveness and tolerability of OROS®-methylphenidate. Pharmacopsychiatry 2007. [DOI: 10.1055/s-2007-991830] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
50
|
|